Sequence-Based Prediction for Vaccine Strain Selection and Identification of Antigenic Variability in Foot-and-Mouth Disease Virus by Reeve, Richard et al.
Sequence-Based Prediction for Vaccine Strain Selection
and Identification of Antigenic Variability in Foot-and-
Mouth Disease Virus
Richard Reeve
1,2*, Belinda Blignaut
3,4, Jan J. Esterhuysen
3, Pamela Opperman
3,4, Louise Matthews
1,2,
Elizabeth E. Fry
5, Tjaart A. P. de Beer
6¤a, Jacques Theron
4, Elizabeth Rieder
7, Wilna Vosloo
3¤b, Hester G.
O’Neill
8, Daniel T. Haydon
1,2, Francois F. Maree
3
1Boyd Orr Centre for Population and Ecosystem Health, University of Glasgow, Glasgow, United Kingdom, 2Institute of Biodiversity, Animal Health and Comparative
Medicine, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, United Kingdom, 3Transboundary Animal Diseases Programme,
Onderstepoort Veterinary Institute, Agricultural Research Council, Onderstepoort, South Africa, 4Department of Microbiology and Plant Pathology, University of Pretoria,
Pretoria, South Africa, 5Division of Structural Biology, The Henry Wellcome Building for Genomic Medicine, Headington, United Kingdom, 6Bioinformatics and
Computational Biology Unit, University of Pretoria, Pretoria, South Africa, 7Foreign Animal Disease Research Unit, United States Department of Agriculture, Agricultural
Research Service, Plum Island Animal Disease Center, Greenport, New York, United States of America, 8Biochemistry Division, North-West University, Potchefstroom,
South Africa
Abstract
Identifying when past exposure to an infectious disease will protect against newly emerging strains is central to
understanding the spread and the severity of epidemics, but the prediction of viral cross-protection remains an important
unsolved problem. For foot-and-mouth disease virus (FMDV) research in particular, improved methods for predicting this
cross-protection are critical for predicting the severity of outbreaks within endemic settings where multiple serotypes and
subtypes commonly co-circulate, as well as for deciding whether appropriate vaccine(s) exist and how much they could
mitigate the effects of any outbreak. To identify antigenic relationships and their predictors, we used linear mixed effects
models to account for variation in pairwise cross-neutralization titres using only viral sequences and structural data. We
identified those substitutions in surface-exposed structural proteins that are correlates of loss of cross-reactivity. These
allowed prediction of both the best vaccine match for any single virus and the breadth of coverage of new vaccine
candidates from their capsid sequences as effectively as or better than serology. Sub-sequences chosen by the model-
building process all contained sites that are known epitopes on other serotypes. Furthermore, for the SAT1 serotype, for
which epitopes have never previously been identified, we provide strong evidence – by controlling for phylogenetic
structure – for the presence of three epitopes across a panel of viruses and quantify the relative significance of some
individual residues in determining cross-neutralization. Identifying and quantifying the importance of sites that predict viral
strain cross-reactivity not just for single viruses but across entire serotypes can help in the design of vaccines with better
targeting and broader coverage. These techniques can be generalized to any infectious agents where cross-reactivity assays
have been carried out. As the parameterization uses pre-existing datasets, this approach quickly and cheaply increases both
our understanding of antigenic relationships and our power to control disease.
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Introduction
The genetically highly variable nature of RNA viruses [1] has
been extensively documented in pathogens such as foot-and-
mouth disease virus (FMDV) and influenza virus. A direct
consequence of this phenomenon is that inactivated or attenuated
vaccines derived from some such highly variable viruses confer
protection only against closely related field strains [2], as has been
amply demonstrated during the 2009 influenza A (H1N1)
pandemic [3]. This feature of the viruses makes it particularly
important to estimate the cross-reactivity, and therefore the likely
cross-protection, between sera derived from the vaccine strain and
field viruses [4,5].
The emergence of antigenically novel viruses, against which
existing vaccines do not provide adequate protection, may require
the selection of new vaccine seed strains. Currently, where no
appropriate vaccine exists, field isolates are, when possible,
adapted for vaccine production, amplified and then processed
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inoculated into animals and tested for efficacy in vitro and
subsequently in vivo. Due to the time and expense required, there
is a limit to the number of isolates that can be submitted to
undergo this procedure, and a sub-optimal choice of vaccine strain
may therefore be made. An in silico predictor that identifies those
strains likely to provide the broadest cross-protection could
therefore substantially enhance capacity to develop appropriate
vaccines rapidly and effectively, whilst minimising the cost and the
need for animal experimentation.
FMDV is ideal for such an approach to vaccine strain selection.
It is a positive-sense, single-stranded RNA virus, the prototype
member of the genus Apthovirus of the family Picornaviridae.I t
exhibits great genomic variability, with 32–33% and 53% amino
acid variability in our data, within and between serotypes
respectively, in the immunogenically important structural proteins,
VP1-VP3 (similar variability has previously been observed in VP1
across all serotypes [7]). Its seven serotypes are not cross-reactive,
but individual vaccines can often protect against large groups of
genetically diverse viruses within a serotype. Nevertheless there are
also antigenically distinct subtypes within each serotype, and this
should allow the discrimination of antigenically important changes
from other substitutions. The virus is endemic in sub-Saharan
Africa where six of the seven serotypes occur, and the South
African Territories (SAT) types 1, 2 and 3 display appreciably
greater intratypic genomic variation than the traditional ‘‘Euro-
Asian’’ types [8–13]. Indeed, distinct genetic variants exist within
these serotypes, with the serotypes being divided into topotypes
based on genetic differences [7].
The variability of all SAT FMDV serotypes requires both a
range of vaccines to provide protection within serotypes and
accurate cross-reactivity testing to guide vaccine selection, with
implications for the control of the disease by vaccination if either
of these is not available. Despite similar genomic variability, SAT2
exhibits significantly higher intratypic antigenic variability than
SAT1 [11]. Such a pair of serotypes with similar genetic but
different antigenic characteristics provide an excellent testing
ground for studies of the genetic basis of antigenic variability.
Furthermore, SAT2 viruses are the causative agent in most
outbreaks of FMDV in cattle in sub-Saharan Africa, and SAT1 is
also widely dispersed, though mostly maintained through persis-
tent infections of African buffalo. This makes them the most
important serotypes to study in the region.
The outer capsid proteins – VP1, VP2 and VP3 – are directly
involved in antigenicity and a large proportion of residues are
exposed on the virion surface (40% in the structure used in this
paper). Amongst the exposed residues are epitopes recognised by
the host immune system. All serotypes are believed to share the
major antigenic site on the flexible G-H loop of the VP1 protein,
which is highly variable between even closely related strains. This
is the only site to have been identified with monoclonal antibody
(MAb) escape mutants for a single SAT2 virus [14], and none have
been for SAT1. However, this and at least four additional sites
have been implicated as neutralising epitopes for serotype O [15–
17], and further epitopes have been mapped for viruses from
serotypes A, O and C using MAbs [15–24].
This antigenic variability is reflected in the virus neutralisation
(VN) titres [25], which provide an in vitro measure of whether the
sites that contribute to the neutralization of the virus remain
sufficiently similar to cross-react. Virus neutralisation is not the
only important determinant of protection [26]; nevertheless the
VN test (VNT) is one of the standard tests for cross-reactivity and
it is considered to provide the most definitive serological results
[6]. Specifically, the current approach uses VNTs to quantify
antigenic relationships through ‘‘r1-values’’ – the ratio of the
heterologous to homologous titres, with a ratio close to 1
indicating the viruses are antigenically similar. Generally r1-values
in the range of 0.4–1.0 are considered to be indicative of
reasonable levels of cross-protection, whilst all values being below
0.2 for a given isolate indicate the need for new vaccine strain
development [27], with 0.3 also proposed as a single threshold
[28]. Many sources of variation are known to influence the
neutralisation titres. However, standard approaches to obtaining
r1-values do not fully account for these different sources of
variability [29]. In order to maximise information available from
neutralisation tests we developed a simple statistical methodology
using multiple data sources, combining data from multiple
experiments conducted at different times.
The availability of sequence data and related titres from VN
testing provides the opportunity to directly relate cross-reactivity to
sequence variation. This relationship would allow prediction of an
important component of vaccine efficacy for candidate vaccine
seed strains, and rapid identification of vaccine match without the
need for new serology work for existing vaccines.
The aim of the current study is to develop an in silico tool to
predict vaccine efficacy using sequence data, neutralising titres and
structural information, and use this tool to identify and quantify
the significance of epitopes of the viruses. We have obtained a
broad spectrum of SAT1 and SAT2 isolates which were
sequenced, and have generated sera from representative viruses.
An extensive serological dataset was generated from VNTs. We
have also used a novel, and currently the only, crystallographic
structure for any SAT serotype to identify surface-exposed residues
on the capsid. Specific objectives were to (i) generate improved
statistical methods of estimating r1-values that maximise the
efficient use of available experimental data, (ii) relate these
estimated antigenic differences to sequence variation, (iii) use this
relationship to predict vaccine match for viruses from sequence
information, and to predict neutralisation titres, cross-reactivity
and hence coverage for vaccine strains, and then (iv) to identify
areas of the capsid containing epitopes.
Results
Virus isolates, sequencing and VNTs
Twenty SAT1 and twenty-two SAT2 viruses (Table 1) repre-
sentative of different topotypes were selected, and full capsid
sequences were generated where not already available. This
collection constitutes fully two thirds of all isolates for which full
capsid sequences exist. Cattle sera were prepared against three
SAT1 and four SAT2 strains. VNTs were carried out with 138
Author Summary
New strains of viruses arise continually. Consequently,
predicting when past exposure to closely related strains
will protect against infection by novel strains is central to
understanding the dynamics of a broad range of the
world’s most important infectious diseases. While previous
research has developed valuable tools for describing the
observed antigenic landscapes, our ability to predict cross-
protection between different viral strains depends almost
entirely on cumbersome and expensive live animal work,
often restricted to model species rather than the natural
host. The development of computer-based approaches to
the estimation of cross-protection from viral sequence
data would be hugely valuable, and our study represents a
significant step towards this research goal.
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possible SAT1-SAT1 pairs and 83 of the 88 SAT2-SAT2, with
between 1 and 11 repeats of each, giving a total of 246 SAT1 and
320 SAT2 titres. This included replicates within individual
experiments, and repeats with different sera and in different
batches (see Materials and Methods for an explanation of the
terminology), in order to determine the significant sources of
variability.
Improving estimates for r1-values
A key feature of our analysis was to develop a formal approach
for including data from multiple sera, experiments and batches.
Table 1. FMDV isolates used in this study.
Serotype Virus strain Topotype Passage history Country of origin GenBank Accession No.
SAT1 KNP/196/91* 1 PK1RS1 South Africa AF283429
SAT1 KNP/148/91 1 PK1 RS5 South Africa GU194495
SAT1 ZIM/HV/3/90 1 BTY1 RS3 Zimbabwe GU194496
SAT1 ZIM/GN/13/90 1 BTY1 PK1 RS3 Zimbabwe GU194497
SAT1 KNP/41/95 1 PK1 RS4 South Africa GU194498
SAT1 SAR/9/81* 1 Epithelium South Africa DQ009715
SAT1 NAM/307/98 2 PK1 RS4 Namibia AY770519
SAT1 ZIM/6/94 2 PK1 RS3 Zimbabwe GU194500
SAT1 TAN/37/99 3 BTY1 RS4 Tanzania DQ009718
SAT1 ZAM/2/93 3 PK1 RS3 Zambia DQ009719
SAT1 ZIM/25/90 3 BTY2 RS4 Zimbabwe GU194499
SAT1 MOZ/3/02 3 PK1 RS5 Mozambique DQ009720
SAT1 KEN/5/98 3 BTY1 RS3 Kenya DQ009721
SAT1 UGA/3/99 4 BTY1 RS4 Uganda DQ009722
SAT1 UGA/1/97 5 PK1 RS4 Uganda AY043300
SAT1 NIG/5/81* 7 BTY2 RS2 Nigeria DQ009723
SAT1 SUD/3/76 7 BTY1 RS3 Sudan DQ009725
SAT1 NIG/15/75 8 BTY1 RS3 Nigeria DQ009724
SAT1 NIG/8/76 8 BTY1 RS5 Nigeria GU194503
SAT1 NIG/6/76 8 BTY1 RS5 Nigeria GU194502
SAT2 KNP/19/89* I BHK4 South Africa DQ009735
SAT2 KNP/2/89 I CFK2 RS2 BHK4 South Africa GU194488
SAT2 KNP/51/93 I PK1 RS6 South Africa GU194489
SAT2 ZIM/1/88 I CFK1 RS4 Zimbabwe GU194491
SAT2 SAR/16/83 I B1 BHK8 South Africa DQ009734
SAT2 ZIM/14/90 II BTY1 RS3 Zimbabwe DQ009728
SAT2 ZIM/17/91 II BTY2 RS4 Zimbabwe DQ009727
SAT2 ZIM/GN/10/91 II BTY2 PK1 RS3 Zimbabwe GU194493
SAT2 RHO/1/48 II BTY2 RS2 Zambia AJ251475
SAT2 ZIM/7/83* II B1 BHK5 B1 Zimbabwe AF540910
SAT2 ZIM/34/90 II BTY3 RS4 Zimbabwe GU194490
SAT2 ZIM/8/94 II BTY1 RS3 Zimbabwe GU194492
SAT2 KEN/8/99 IV BTY2 RS4 Kenya AY254730
SAT2 GHA/8/91 V BTY1 RS3 Ghana DQ009732
SAT2 SEN/5/75 V BTY1 RS1 BHK5 Liberia DQ009738
SAT2 SEN/7/83 VI CK1 RS1 Senegal DQ009733
SAT2 SAU/6/00 VII BTY1 RS1 Saudi Arabia AY297948
SAT2 ERI/12/89* VII BTY2 PK1 RS5 Eritrea GU194494
SAT2 RWA/2/01* VIII PK1 RS1 Rwanda DQ009730
SAT2 ANG/4/74 XI BTY3 RS3 Angola DQ009736
SAT2 UGA/2/02 XII PK1 RS1 Uganda DQ009731
SAT2 ZAI/1/74 XII BTY2 RS4 Zaire DQ009737
Protective strains are starred.
doi:10.1371/journal.pcbi.1001027.t001
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serum to calculate an r1-value controls for between-serum
variability [25], and in order to control for between-experiment
variation, at least three repetitions are officially advised [6] – when
more than one of either the homologous or heterologous VNT is
carried out, then the results are usually averaged [30]. Our aim
was to go beyond this, and combine all available titres measured in
all batches for every pair of protective strain and challenge virus to
produce a coherent set of best estimates for all of the true
underlying r1-values simultaneously.
This was achieved by first determining the presence or absence
of and then estimating the magnitude of any consistent inter-
experiment, inter-batch or other variability in the data. We built a
linear mixed-effects model with log titre of the challenge virus
versus protective strain as the response variable. The challenge
virus (p=10
244), protective strain (p=10
212) and their interaction
(p=10
227) were significant fixed effects, but neither serotype nor
whether sera were prepared by vaccination or infection was found
to be significant. We would not have expected to see this latter
effect since it was confounded with protective strain as all sera for
each strain were generated by only one of vaccination or infection.
A random effect at the level of experiment accounted for the inter-
experiment variability. By comparing models with random effects
to allow for other sources of variability, we determined that there
was consistent variability between sera (p=10
215), but not
between batches (see Materials and Methods). Apart from the
one identified above, other interactions between these effects
(protective strain, challenge virus, serum and experiment) were not
found to be significant. This ‘‘best consensus estimate’’ model
could thus be written as:
log(tp,c)~mp,czeSzeEzeR
where ei*N(0,s2
i )
ð1Þ
where tp,c is the titre for a neutralisation test for protective strain p
and challenge virus c, mp,c is the mean log titre, eS and sS
2 are the
best linear unbiased predictor and associated variance for the
random effect of serum, eE and sE
2 are the equivalent measures for
experiment, and eR and sR
2 are the model residuals and associated
variance.
Estimates of these variances were used to examine the expected
uncertainties associated with standard methods of estimating r1-
values. The between-serum variance was 0.072, which gives a
95% confidence interval around the estimate of +/20.53 log titres
due to inter-serum variability; as was noted earlier, this is
eliminated by always using homologous and heterologous titres
from the same serum to calculate an r1-value. However, the
remaining (between-experiment and residual) variances sum to
0.287, which gives a 95% confidence interval around the estimate
of an individual serological r1-value (i.e. using 1 homologous titre and 1
heterologous titre from the same serum in the same batch, as is
usually the case) of +/21.49 log titres. With test variability this
high it is clear that an improved method of estimating r1-values
that makes use of all available data would be valuable.
Estimates of mp,c had 95% confidence intervals ranging between
+/20.50 to +/21.17 log titres, depending on the number of titres
available (the greatest uncertainty being associated with r1-values
estimated from only a single homologous and heterologous titre).
These narrower confidence intervals show that our new techniques
for estimating mp,c provide a substantial improvement on existing
methods for the same number of titres. These best consensus
estimates of the true means were therefore used as our gold
standard for subsequent analyses (Figure 1 and Dataset S1).
Relating antigenic differences to sequence variation
Structural data were used to identify candidate areas of the
capsid that might be antigenically significant (29 and 28 areas for
SAT1 and SAT2 respectively – see Materials and Methods for
details). These provide the starting point for a related linear mixed-
effects approach used to predict r1-values from the sequence data
and, ultimately, to identify antigenically significant areas of the
capsid. The mean log titre, m – the fixed effect term in the
estimating model (Equation 1) – was replaced with a predictive
term based on differences between capsid-coding sequences of the
protective and challenge strains. Removing this fixed effect also
necessitated the inclusion of the additional random effect of
challenge virus (eC*N(0,s2
C),p ,10
210), and the final model took
the form:
log(tp,c)~k0z
X N
i~1
ki|di(p,c)zeSzeEzeCzeR ð2Þ
where k0 is the average titre and di is a raw count of the number of
amino acid changes between the protective strain and challenge
virus in a single candidate area identified from the structural
modelling (the i
th out of a total of N areas identified as potentially
antigenically significant – see Materials and Methods for the
model selection process), with ki the regression coefficients.
Predictive model requirements: Vaccine selection and
vaccine coverage
Two different predictions are of interest: first, in an outbreak,
the vaccine that best matches a given challenge virus, and second,
to judge breadth of coverage of a candidate vaccine strain – the
range of r1-values that it will produce for selected challenge
viruses. Correspondingly, models were validated using two
measures of quality of a predictor of antigenic distance: (i) the
number of times the protective strain with the predicted highest r1-
value for a given challenge virus matches the strain that would be
selected using the serology data; and (ii) the difference between the
predicted r1-values for specific pairs of protective strains and
challenge viruses and our best consensus estimate r1-values for
those pairs. In the former case only those challenge viruses that
might have appropriate protective strains are considered (we chose
those with an estimated r1$0.2) since we are not interested in
whether the model correctly chooses the least worst vaccine when
none could possibly be effective.
Specifically, candidate models selected by the model-building
process were cross-validated by estimating parameters in two
different ways, corresponding to our two different requirements: (i)
using datasets missing all data for each challenge virus in turn, and
comparing the vaccine choice with that obtained using our gold
standard estimates; or (ii) using datasets missing all data for each
protective strain in turn, and comparing the r1-values generated
for that missing protective strain compared with our gold standard
estimates. The best models for each serotype are reported below.
Vaccine match prediction for new virus isolates
Eighteen out of the 20 SAT1 viruses but only 9 out of the 22
SAT2 viruses had protective strains close enough to offer some
cross-reactivity (r1$0.2), and so were included in the cross-
validation. For SAT1 the best model after cross-validation
contained two terms, the number of amino acid changes in the
VP1 G-H loop and beyond (residues 132–174, which contains the
major antigenic site for FMDV as well as sites in the H-I loop), and
in the VP3 H-I loop (residues 191–202, which contains amino
acids identified by MAb escape mutant studies as part of the
Antigenic Variability in Foot-and-Mouth Disease
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visualization. The formula for the r1-value predictor is:
r1(p,c)~0:933d1GHz(p,c)|0:753d3HI(p,c)|e{eC(p) ð3Þ
where the eC are the best linear unbiased predictors from Equation
2. For SAT2 the best model contained three terms: the number of
amino acid changes in the VP1 C terminus (residues 200–224,
which contains Site 1b on O, Sites C and D on serotype C, Site 2
for A10, Sites 3 and 4 for A12 and Site 2 for A5 – [21], and
references therein), in the VP2 B-C loop (residues 70–82, which
contains Site 2 on O, Site 3 on A10, Site 1 on A5 and another part
of Site D on C – [21], and references therein), and residue 178 in
the VP1 H-I loop (the H-I loop as a whole contains Site 1 for A12
Figure 1. Heatmap and clustering analysis of virus neutralisation titres. Two-dimensional hierarchical clustering of viruses and antisera for
SAT1 (left) and SAT2 (right). Viruses were clustered according to their neutralization profiles along the vertical axis. Simultaneously, the antisera were
arranged according to their abilities to neutralise the panel of viruses along the horizontal axis. Dendrogram patterns are shown to the left (for
viruses) and top (for antisera). The color key for neutralization data points is shown in the histogram in the top left of each plot along with the count
of viruses with each titre.6indicates the absence of data.
doi:10.1371/journal.pcbi.1001027.g001
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red, for visualization. The formula is:
r1(p,c)~0:748d1CT(p,c)|0:709d2BC(p,c)|0:770d1HI(p,c)|e{eC(p) ð4Þ
The predictive models successfully identified 13 SAT1 matches
(72%) and all 9 SAT2 matches (100%) (Figure 3). This accuracy is
comparable with that obtained using the individual serological
measurements, which, by bootstrapping the raw titres to generate
individual serological r1-values, we estimated would correctly
identify the best strain 70% of the time for SAT1 and 83% for
SAT2 (a multinomial test on these values shows that there is no
significant difference between the serological and predicted
values). Though additional serological and sequence data would
ultimately improve the predictive model, it currently performs at
least as well as standard serological approaches.
r1-value prediction for new vaccine candidates
A small bias was observed for all of the candidate models in
their predictions for heterologous titres relative to homologous
titres. This does not affect the vaccine match experiments where
the aim is to reduce relative error (in the differences between r1-
values for different protective strains using the same challenge
virus) potentially at the expense of absolute error (in the r1-values
themselves). In this case, however, for accurate r1-value prediction
the aim is to reduce this absolute error. Adding a term to the
models that explicitly distinguished homologous and heterologous
titres removed this bias, and so it was included in all of the
candidate models.
The best predictive model of r1-values following cross-validation
for SAT1 contained the same two terms as before (the number of
amino acid changes in the VP1 G-H loop and beyond, and the
number in the VP3 H-I loop), together with a term that is present
when titres are heterologous. The formula is:
r1(p,c)~0:964d1GHz(p,c)|0:743d3HI(p,c)|0:434½p=c 
|eeC(c){eC(p)
ð5Þ
Ninety eight percent of the predictions (Figure 4, SAT1, black
crosses) are within the 95% confidence limits of the gold standard
estimates (dashed lines), which is significantly better than achieved
by individual serological r1-values (grey dots) at 87% (Fisher’s
exact test, p,0.01). The variance around the gold standard
estimates is significantly lower for the predictions than the
individual serological r1-values (0.09 rather than 0.18, Bartlett
test, p,0.01).
The best predictor of r1-values for SAT2 also contained the
same three terms as before (the VP1 C terminus, the VP2 B-C
loop, and a single residue in the VP1 H-I loop), again together
with a term for heterologous titres. The formula is:
r1(p,c)~0:906d1CT(p,c)|0:801d2BC(p,c)|0:847d1HI(p,c)
|0:284½p=c |eeC(c){eC(p)
ð6Þ
For SAT2, 77% of the predicted r1-values were within the
confidence limits of the gold standard estimates (Figure 4, SAT2,
black crosses), which is not significantly different from 66% for
individual serological r1-values (grey dots). Variances were also not
significantly different (0.40 compared to than 0.43). Both
predictions and serological measurements are less accurate than
those for SAT1 due to the lower repeatability of SAT2 serology
(Figure 4, grey dots).
Identifying epitopes by controlling for phylogenetic
structure
The above predictive models identify those areas that are
correlated with loss of cross-reactivity. To identify those areas that
are directly responsible for antigenic variability it is necessary to
develop models that additionally control for the phylogenetic
relationships between virus strains. The phylogenetic control
extends Equation 1 in an analogous manner to the predictive
model (Equation 2):
log(tp,c)~k0z
X N
i~1
mi|di(p,c)zeSzeEzeR ð7Þ
where di is a delta function which is 1 if p and c are separated by
branch i of the phylogenetic tree and 0 otherwise. Loss of cross-
reactivity is caused by amino acid substitutions in the capsid
proteins, and any individual substitution must occur in a specific
branch of the phylogenetic tree (though we may not be able to
determine which). Each branch partitions the tree into two groups,
and where a branch effect represents changes that impact
significantly on cross-reactivities, they will be higher between
viruses within the groups than those between groups (after
controlling for other effects). For instance, where a terminal
branch is identified, the fixed effect of that branch specifies an
amount by which the virus to which it leads (the first group) is
Figure 2. Antigenically significant areas of the SAT1 and SAT2
capsids. The image shows the area around one of the five-fold axes of
symmetry of the capsid (centre). Changes to blue areas were used as
predictors of loss of cross-reactivity for SAT1, while changes to red areas
were used for SAT2. The two residues identified as parts of an epitope –
residue 138 on the VP3 E-F loop and residue 198 on the VP2 H-I loop –
are coloured white. Note that these two residues and the other areas
are repeated multiple times in the image due to structural symmetries
in the capsid.
doi:10.1371/journal.pcbi.1001027.g002
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significant internal branch, similarly, identifies a clade that is
antigenically distant from the rest of the tree. By building a model
containing all of the branches in the tree, and then using a stepwise
elimination procedure to remove branches which do not
significantly improve the model fit (p.0.05), we are left with the
set of branches that, when traversed, significantly account for
reductions in antigenic cross-reactivity.
Twelve phylogenetic branches are significant in SAT1 and
twenty-one in SAT2 (black lines, Figure 5). For SAT1 these are six
branches that each partition individual topotypes from the rest of
the tree, and five terminal branches that lead to viruses for which
large numbers of titres have been obtained (including the three
protective strains) as well as one that is antigenically very distant
from the protective strains (ZAM/2/93, which has no r1-value
above 0.2). For SAT2, there are six internal branches throughout
Figure 3. Vaccine matching using sequence data. Charts show the number of times that the best protective strain estimated using the full
serological dataset (header) agrees with the predicted best strain using the sequence data (black bars) or the estimated strains using bootstrap
samples of individual serological r1-values (grey bars). White bars are errors, where the predicted/individual r1-values gave a different protective
strain.
doi:10.1371/journal.pcbi.1001027.g003
Figure 4. Predicting cross-reactivity using sequence data. Bootstrap samples of individual serological r1-values (grey dots), predictions (black
crosses) and matching best consensus estimates – our gold standard – and their confidence limits (black dots and dotted lines) against best
consensus estimates for SAT1 and SAT2 r1-values. Because of the log-normally distributed variance structure of the r1-values, data are plotted on a log
scale.
doi:10.1371/journal.pcbi.1001027.g004
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viruses that are antigenically distinct (again, all r1-values are below
0.2) and five other viruses (including the four protective strains).
Any model containing these terms controls as completely for the
phylogeny as is possible with the data available, and should a
model have a significantly better fit than the phylogenetic model
on its own, it must achieve this by some mechanism other than
phylogenetic correlation. A simple combination of Equations 2
and 7 provides a potential model, with an additional term for the
raw count of the number of amino acid changes between the
protective strain and challenge virus in a single candidate area:
log(tp,c)~k0zk1|d1(p,c)z
X N
i~1
mi|di(p,c)zeSzeEzeR ð8Þ
where d1 is the count of substitutions at a specific site, and k1 the
associated regression coefficient. The phylogenetic control terms
account for repeated measurement of all significant shared
phylogenetic history. However, in doing so, they remove all
significant direct effects of substitutions at individual branches of
the tree, but are not designed to capture the interactions involved in
multiple and/or convergent substitutions at the same sites in
different branches. Consequently, the substitution count in any area
significantly improves the model if it corresponds to this substitution
structure. Parallel and/or back-mutations, relatively frequent in
such highly variable viruses, are therefore strong signals used by the
model to determine antigenically significant areas. The phyloge-
netic control is therefore conservative in that significant sites with
substitutions at only one branch in the tree will not be identified, as
the different substitutions in that branch cannot be readily
disambiguated. Nevertheless, after controlling for phylogeny, the
twenty-nine SAT1 areas tested with the model were collectively
significant predictors (p,0.05 [31]), but the twenty-eight areas for
SAT2 were not significant (collectively or individually).
Because substitutions are ultimately responsible for the loss of
cross-reactivity, the substitutions contributing to counts in these
SAT1 areas must be responsible for this loss unless they are co-
occurring with causative substitutions. Any such causative
substitutions should, however, be identifiable because substitution
counts in areas containing them will improve the model fit.
Comparing the individually best SAT1 areas from above with
bootstrapped random sequences of the same length from other
parts of the capsid, however, fails to identify other causative
substitutions, and eight areas were instead found to be significant
after a Holm-Bonferroni correction for the number of terms [32]
(p,10
212 collectively). Of these eight terms, seven were
individually significant in the previous test (p,0.05). These seven
terms consisted of five that corresponded exactly to the five areas
identified as the constituent parts of the Site 3 conformational
epitope for A10 [24] (p,10
28 collectively), one was the VP1 G-H
loop (p,0.001), and the last was the VP3 G-H loop, previously
identified as Site 3 on A12 [18] (p,0.01).
To identify the specific residues responsible for these drops in
antigenic cross-reactivity, Equation 8 is trivially modified to test
substitutions to the 62 individually variable residues in the seven
areas identified (instead of the 29 candidate areas). Again, this is a
conservative test, as it will only identify residues where multiple/
convergent substitutions occur at different branches in the
phylogeny. Collectively, changes to the residues are significant
after controlling for phylogeny (p,0.005), but only two residues
are individually significant (p,0.05). Bootstrap comparisons with
other residues showed these to be the two most significant
predictors of loss of cross-reactivity out of all the residues in the
capsid, and both are adjacent to residues identified by MAb escape
mutant studies on A10 as part of Site 3 [24]. These were residue
138 on the VP3 E-F loop and residue 198 on the VP2 H-I loop –
see Dataset S2 for alignment, and Figure 2, white, for visualization
– and the expected effects of substitutions at those residues are a
reduction in cross-reactivity of 25% (95% CI 8%–40%) and 16%
(95% CI 0%–30%) respectively.
To test whether areas and individual residues vary in their
significance across the whole serotype or are conserved, a random
effect (k(r) in Equation 9) that allows the count (k1 in Equation 8)
to vary in significance for different protective strains, challenge
viruses or sera (r) can be added to the model:
log(tp,c)~k0zk(r)|d1(p,c)z
X N
i~1
mi|di(p,c)zeSzeEzeR
where k(r)*N(0,s2
k)
ð9Þ
Figure 5. Phylogenetic trees indicating the branches controlled for in the analysis. SAT1 and SAT2 phylogenetic trees, showing protective
strains (red, starred) and branches associated with significant drops in antigenic cross-reactivity (black lines, p,0.05). Topotypes are shown for SAT1.
The origin and passage history of each virus is described in Table 1.
doi:10.1371/journal.pcbi.1001027.g005
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all areas and individual residues). For SAT2, however, although no
areas or residues are significant individually, thirty-one of them
have significant interactions (p,0.05) with at least one of these ‘r’
terms, which suggests that there may be some variability in the
significance of parts of the capsid for loss of cross-reactivity within
the serotype.
Discussion
The identification of antigenic sites on individual FMDV
isolates is time consuming, with the consequence that data are not
available for all serotypes, much less for all isolates. Indeed, very
little is known about the important epitopes for SAT1 and SAT2
viruses, impacting on the potential to both design vaccines with
broader or better targeted antigenic cover and predict the efficacy
of a particular vaccine strain against circulating viruses in the field.
We have identified seven areas containing what we believe to be
three epitopes for SAT1, and we provide evidence that these are
conserved across our whole sample. We have further quantified
the effect of substitutions at two specific residues in one of these
epitopes. The conservative phylogenetic control employed
throughout the analysis means that this may not be an exhaustive
list of antigenically significant areas of the capsid, and is almost
certainly not for residues, as it will only identify ones where
multiple/convergent substitutions occur at different branches in
the phylogeny. The areas that are identified do, however,
correspond to epitopes identified by MAb escape mutants for
other serotypes, and both of the specific residues found are (after
alignment) adjacent to ones which are part of Site 3 on A10 [24].
Confirmatory evidence that the phylogenetic control is acting as
expected is provided by the fact that for SAT1 all of the internal
branches that are identified as antigenically significant correspond
to previously identified antigenically important events, that is to
say branches that partition individual topotypes from the rest of
the tree. For SAT2, we have identified variability in the
significance of different sites for different protective and challenge
strains, and even different sera, that may indicate epitopes are
present on some viruses but not on others. This may help to
explain the much greater observed antigenic variability in SAT2
compared to SAT1 despite their similar genomic variability [11],
as well as the absence from our analyses of identifiable epitopes
that are conserved across the serotype.
We have also used cross-reactivity data generated for SAT1 and
SAT2 FMDV to develop a linear mixed-effects model that uses
replicates and repeated experiments to more accurately account
for variability in measurement and so generate better estimates of
cross-reactivity for FMDV. We have enhanced this model with
sequence and structural data to identify surface-exposed residues
that correlate with loss of cross-reactivity and then built models
using counts of amino acid substitutions in selected areas to predict
cross-reactivity. We note that all of the areas used in these models
are associated with epitopes identified by MAb escape mutants for
other serotypes. Furthermore, for SAT1 they also correspond to
parts of the new epitopes identified above.
These predictive models were used to successfully identify the
efficacy of novel candidate vaccines against the virus isolates, with
98% of SAT1 predictions within the 95% confidence intervals for
our gold standard estimator of true r1-values, and 77% of SAT2
predictions. For SAT1 this was significantly better than individual
serological r1-values despite the predictions being made without
the use of any sera from the protective strains. Related models
were also used to predict the best vaccine match for novel virus
isolates. For the 9 SAT2 virus isolates for which any match existed
in the data (r1$0.2), the model correctly predicted all 9, and for
the 18 SAT1 isolates, the model predicted 13. In both cases there
is no significant difference between the model predictions and the
serological results. The uncertainty inherent in the VNT and the
variability between different experiments balance any inaccuracies
in the predictive model, making it at least as effective a measure of
r1-value and vaccine match as serology itself unless the latter is
repeated multiple times. Improving the serological tests is an area
of active research [33], and we anticipate being able to improve
the predictive models further by exploiting such improved
serological datasets.
The accuracy of the r1-value predictions and the inaccuracy of
the matching for SAT1 (relative to SAT2) may have the same
cause – two of the anti-sera were raised against viruses of the same
topotype (topotype 1 – constituting 70% of the titres), producing a
good model for that topotype, but with little power to generalise
and predict cross-reactivity for significantly different viruses
clustering in other topotypes. Consequently, it identified 8 out of
10 correctly when the answer was a topotype 1 vaccine, but only 5
out of 8 for the other topotype. Conversely, the relative inaccuracy
of the r1-values but the accuracy of the matching for SAT2 may
share the opposite cause – 4 anti-sera were raised against 4
different topotypes, giving a better estimate of which areas were
antigenically significant in general and thereby allowing better
vaccine matching. However, because of the relative sparsity of
data from any individual topotype (there were at most 92 titres for
any individual topotype for SAT2, against 170 for SAT1), we
obtained a poorer estimate of the relative importance of each area,
and therefore a less accurate r1-value prediction. The greater
inherent variability in SAT2 titres also necessitated more data to
acquire an accurate estimate. These complementary results
suggest that to refine the model further more data from different
topotypes will improve the vaccine matching in SAT1, and more
from the same topotypes will improve the estimates of cross-
reactivity in SAT2.
The VP1 G-H loop is known to contain major epitopes in all
serotypes of FMDV where MAb studies have been conducted;
substitutions in it are therefore considered to be a significant
determinant of loss of cross-reactivity. Our SAT1 epitope analysis
identified this loop and the model used it to predict cross-
reactivity. However, our SAT2 model did not find the number of
amino acid substitutions in the candidate area containing the loop
to be in general a good correlate. There are three potential
explanations. First, the G-H loop has a high substitution rate, so
high indeed that we suggest that the epitope(s) may very often not
cross-react even between closely related strains, giving the model
little data with cross-reacting epitopes from which to identify a
pattern. Second, the candidate area is much bigger than just the
G-H loop, therefore including many residues that are not
antigenically significant. Finally saturation can occur, causing the
actual count even inside the G-H loop to cease to be meaningful.
The combination of these effects makes it very difficult to detect
the signal of epitope loss from the noise of other substitutions.
Better predictors might be obtained by selecting smaller
candidate areas. However, there is a risk of ‘‘fishing’’ until an
appropriate sub-sequence is discovered, leaving the generality of
the technique uncertain. Related work on influenza A [34,35],
which was the first to attempt this kind of prediction, examined
101 residues (chosen based on previous laboratory identification of
antigenic sites) and built models containing up to 19 terms, testing
orders of magnitude more models than our 2-/3-term out of 28-/
29-area models. The advantage of the approach taken here is that
the areas to be examined were determined by a single a priori
criterion, the strategy for choosing models to test was fixed in
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the model-building process was easily controlled for by a simple
statistical correction.
A further strength of our approach is that it identifies
antigenically significant areas. These can be validated entirely
independently through comparison with MAb escape mutant-
derived epitope information. Of the 5 areas identified here, all
have been identified by previous MAb work in other serotypes.
Furthermore, the two SAT1 areas are specifically identified in
separate analyses as containing epitopes for this serotype, which
provides further strong evidence that the model is indeed
predictive rather than merely correlative. For SAT2 the evidence
is weaker since the epitopes have only been identified on other
serotypes, and the evidence that there may be epitopic variability
within the serotype suggests that more caution should be applied
in using them to predict the cross-reactivity of distantly related
isolates.
This work could be further validated by a reverse-genetics
approach targeting the specific SAT1 residues identified as
antigenically significant. Our methodology could be used to
evaluate the effect of amino acid substitutions by predicting
coverage against a panel of circulating viruses, allowing potential
vaccine candidates that are expected to better match the panel to
be easily identified. Interestingly, because of the high substitution
rate obscuring any signal in the VP1 G-H loop, identified
substitutions would probably not be located in the major antigenic
site of FMDV but instead be found in other antigenically
important areas.
The technique developed here can be used directly for any
FMDV serotype and potentially for any similar virus where cross-
reactivity, sequencing and structural studies have been carried out,
both to identify epitopes, and to predict vaccine match for new
isolates and estimate efficacy of new candidate seed strains. This
can be done by exploiting historical datasets, and is therefore a
quick, low cost and valuable method for better understanding
antigenic relationships. In summary, the use of sequence data to
predict antigenic relationships is a powerful tool that has the
potential to be applied to a variety of different infectious agents.
Materials and Methods
Ethics statement
All procedures were approved by the Onderstepoort Veterinary
Institute Animal Ethics Committee according to national animal
welfare standards.
Virus isolates, RT-PCR and nucleotide sequencing
The viruses were either supplied by the World Reference
Laboratory for FMD at the Institute for Animal Health, Pirbright
(United Kingdom) or form part of the virus databank at the
Transboundary Animal Diseases Programme (TADP), Onderste-
poort Veterinary Institute (South Africa). Viral RNA was extracted
from cell-culture-adapted isolates and cDNA synthesised [36]. The
sequences for the P1-2A-coding regions were obtained via RT-
PCR of viral genomic RNA using existing primers [36–39]. Direct
DNA sequencing of the P1-2A region derived from a given FMDV
isolate yielded a master sequence representing the most probable
nucleotide for each position of the sequence. Due to the
quasispecies nature of FMDV populations, polymorphisms were
detected in some nucleotide positions. Nevertheless, all positions
could be unambiguously assigned to a single nucleotide due to the
high degree of redundancy generated by a genome-walking
approach. Contigs for the ca. 2.2kb region were compiled using
Sequencher
TM vs4.7 (Gene Codes Corporation). Since these are
protein-coding regions, the amino-acid sequences were aligned
with ClustalW (v.1.83) and this alignment was then used to align
the nucleic-acid sequences.
Animal sera and virus neutralisation test
The antigenic diversity of the field isolates was determined using
virus neutralisation assays in micro-titre plates using IB-RS-2 cells
as the indicator system [25]. Cattle sera against reference SAT1
and SAT2 viruses were prepared by two consecutive vaccinations
(vaccinated at day 0, boosted at day 28 and bled at day 38) using
the following vaccine strains: SAT1: SAR/9/81 and KNP/196/
91 (both topotype 1, see Table 1); SAT2: ZIM/7/83 (topotype II)
and KNP/19/89 (topotype I) or convalescent sera obtained from
21 days post-infected cattle for SAT1: NIG/5/81 (topotype 7);
SAT2: RWA/2/01 (topotype VIII) and ERI/12/89 (topotype
VII). Cattle were housed in the isolation facility at TADP and all
procedures were approved by the Onderstepoort Veterinary
Institute Animal Ethics Committee. The neutralisation assays
were performed against viruses from the various topotypes as
indicated in Table 1 after their adaptation on IBRS-2 cells. The
end point titre of the serum against homologous and heterologous
viruses was calculated as the reciprocal of the last dilution of serum
to neutralise 100 TCID50 in 50% of the wells(ibid.).
Structure
The crystal structure of the SAT1 BOT/1/68 capsid was solved
at a resolution of 3A ˚ (Fry et al., unpublished) (Protein Data Bank
ID: 2wzr, r2wrsf). This is the only structure in existence for any
SAT1 or SAT2 virus. SAT1 amino-acid sequence alignments were
compiled with ClustalW. Structures were visualised and the
surface-exposed residues identified with the PyMol Molecular
Graphics System v1.2r0 (DeLano Scientific LLC). Exposed
regions of SAT2 were approximated by alignment with the
SAT1 structure.
The aligned SAT sequences were classified according to
whether they coded for surface-exposed residues or not as
determined from the above structure. Those that did were
grouped into the longest possible contiguous sub-sequences where
all of the residues were surface exposed. Forty-three such sub-
sequences were found, which broadly corresponded to the loops
and termini of the VP1, VP2 and VP3 proteins, though some
loops were not exposed, and some divided into more than one sub-
sequence separated by hidden sections. This division was chosen as
the simplest way of breaking the full sequence down into a number
of candidate areas each of which might be implicated in one or more
antigenic site(s). Of these, 14 of the sub-sequences were invariant
in SAT1, as were 15 of the areas in SAT2, leaving 29 and 28 areas
respectively in the two serotypes to test as possible predictors (see
Dataset S2 for the areas identified).
Although the areas identified for SAT2 were only an
approximation to the true surface exposed areas for that serotype,
residues from every known epitope of FMDV were contained
within these regions [14–24], and so the areas are likely to be
sufficient.
Phylogenetic analysis
A phylogenetic tree was generated from the nucleotide sequence
data using a relaxed uncorrelated exponential clock, and a
GTR+CP112+C112+I nucleotide model [40]. This was identified as
the best model using Bayes Factor analysis [41], although all
similar models produced the same tree topology. All of these
models and analyses are included in BEAST version 1.5.3 and
Tracer version 1.5.0 [42].
Antigenic Variability in Foot-and-Mouth Disease
PLoS Computational Biology | www.ploscompbiol.org 10 December 2010 | Volume 6 | Issue 12 | e1001027Data
The experimental variables used in this study are described
below.
N Protective strain: the virus strain against which each animal
has been previously vaccinated or with which it has been
infected;
N Vaccination status: whether the animal acquired protection
through vaccination (1) or infection (0);
N Serum: each serum is drawn from a single animal, so serum
labels correspond to individual donor animals;
N Challenge virus: virus isolate used in neutralisation
experiment;
N Serotype: serotype of the protective (and challenge) strain;
The neutralisation tests were grouped into experiments where the
same serum was used at the same time with the same challenge
virus (tests within an experiment are replicates); different experi-
ments were grouped into batches by the time at which they were
performed. Possible variability at these levels was investigated
when building the model. Our gold standard best consensus
estimates of r1-values are available in Dataset S1; raw serological
data is available on request.
Statistical modelling and model selection
There were five stages to the statistical modelling:
1. First, a linear mixed-effects model [43] was built with log titre
of the VNTs as the response variable (which are normally
distributed – Lilliefors normality test, p.0.5) – using raw titres
gave us neither normally-distributed (p,10
215) nor homosce-
dastic residuals [30] – using the R statistical software [44] and
the modelling package lme4. This model allowed accurate
estimation of r1-values from serological data.
2. The fixed effects in this model (Equation 1) were then replaced
with sequence-based predictors (a selection of counts in
candidate areas and the count of total amino acid substitutions
were used to test the model), and the model selection approach
outlined below used to generate a model that predicted cross-
reactivity directly from sequence data (Equations 2–6).
3. These were replaced in turn with phylogeny-based effects (see
below) to control for the phylogenetic structure of the data
(Equation 7).
4. Individual areas and residues were added to this model to
identify epitopes (Equation 8).
5. Finally, within-serotype variability in epitopes was investigated
(Equation 9).
Model selection. The predictive models (Equation 2) were
generated by sequentially adding the count of non-synonymous
changes in each of the candidate antigenic areas as a fixed effect in
a standard stepwise regression which continued for a variable
number of steps until no further terms could be added.
Specifically, the probability that each model was a significantly
better predictor than its precursor was assessed by a likelihood
ratio test since the models were nested. For multiple tests each with
p-values pi, the statistic 22 S log pi is expected to be x
2 distributed
with twice as many degrees of freedom as tests under the null
hypotheses [31]. When this was not the case (p,0.05), then the
best predictors that were individually significant (after a Holm-
Bonferroni correction for the number of terms [32]) were used as
bases for the next step of the regression. The stepwise regression
technique was repeated until no more terms could be added to
form a small set of candidate models. The best of the final models
were then cross-validated. Details of the best models are found in
the results (Equations 3–6).
Controlling for phylogeny. Amino acid substitutions on the
capsid (including those identified above) are correlated with
antigenic distance; this could be a direct relationship or may arise
indirectly via relationships between substitutions, phylogenetic
history and antigenic drift, as is found in influenza A [45].
Neglecting to control for evolutionary history has caused false
positive rates of between 20 and 40% in similar analyses [46];
these arise because substitutions that constitute the shared history
of virus pairs have only occurred once and therefore constitute
only a single independent piece of evidence that these substitutions
are important. To account for these repeated measures it is
necessary for us to implement phylogenetic control.
However, existing mechanisms for controlling for phylogeny
focus on properties (or traits) of the leaves of tree and not the
relationships between them [47]. Indeed it is these relationships
(the contrasts) that are used to control for the evolutionary history,
whereas for us these are the signal – the cross-reactivity. We wish
instead to identify the causes of the changes in cross-reactivity
while controlling for the common evolutionary history.
In practice, each branch on the phylogenetic tree (see above)
represents a set of common substitutions by which any pair of
viruses either side of the branch differ (unless multiple and/or
convergent substitutions have occurred). Any comparison of
antigenicity between two viruses either side of the branch will be
affected by those changes. A fixed effect is therefore added to the
model for each branch (di, Equation 7); this is non-zero if the
branch is travelled (and thus these changes have occurred) in the
traversal of the tree between the protective strain from which the
serum is derived and the virus isolate in a cross-reactivity test.
Including these terms in the analysis controls for repeated
measures of this traversal.
Because of the necessarily limited number of protective strains
we do not explore every path through the tree, and so there is
some ambiguity in the allocation of weights to branches (essentially
we have more unknowns than equations). These ambiguities mean
that the models cannot be used predictively, but this does not
prevent their use for phylogenetic control.
Model development begins by constructing a model with the
maximal set of fixed effects; these are then removed using stepwise
regression until all of those left significantly improve the model fit
(p,0.05). In this manner we have controlled for repeated
measures of every significant piece of shared phylogenetic history.
Because the phylogenetic trees are different for the two serotypes
the serotypes are modelled separately.
Identifying epitopes. The phylogenetic control terms
account for repeated measurement of all significant shared
phylogenetic history. However, in doing so they remove all
significant direct effects of substitutions at individual branches of
the tree. Consequently, the substitution count in any area can only
significantly improve the model if it corresponds to multiple and/
or convergent substitutions at the same sites in different branches.
Modelling phylogenetic control in this way therefore provides a
conservative estimate of the number of areas that directly affect
antigenicity.
Sequence-based predictors were added to the models – again,
substitution counts for each of the candidate areas identified in the
structural analysis – to determine which sub-sequences were the
best predictors after controlling for phylogeny (d1, Equation 8), and
these were then compared to bootstrapped samples from the
remaining capsid surface (randomly assembled sub-sequences of
the same length as each candidate). Since changes to the capsid
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specified sub-sequences to the rest of the capsid after controlling
for phylogenetic structure directly determines whether these areas
contain true predictors or whether they contain correlates, with
the true epitopes being found elsewhere. To identify the individual
constituent residues of epitopes, exactly the same mechanism is
used on individual residues instead of areas.
Detecting within-serotype variability. In order to
determine whether there was variability in the effects of
substitutions at specific sites within a serotype, we added a
random effect that allows the effect of the count to vary for
different protective strains, challenge viruses or sera (Equation 9).
Should one of these terms be found to improve model fit, this
would provide evidence that there is variability across the
phylogeny as to the importance of different sites.
Supporting Information
Dataset S1 Best consensus estimates of all r1-values used in the
study.
Found at: doi:10.1371/journal.pcbi.1001027.s001 (0.03 MB XLS)
Dataset S2 Reference alignment of the protective strains to the
study isolates. The dataset shows the VP2, VP3 and VP1 proteins
of the protective strains after alignment to all of the SAT1 and
SAT2 isolates used in the study. The 43 contiguous surface-
exposed areas identified by the capsid structural analysis are
highlighted. Areas with no amino-acid variability are in grey, and
areas with variability are in red for the serotypes for which there is
variation.
Found at: doi:10.1371/journal.pcbi.1001027.s002 (0.14 MB
DOC)
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